A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) †
Titel:
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) †
Auteur:
Blumenschein Jr, G.R. Smit, E.F. Planchard, D. Kim, D.-W. Cadranel, J. De Pas, T. Dunphy, F. Udud, K. Ahn, M.-J. Hanna, N.H. Kim, J.-H. Mazieres, J. Kim, S.-W. Baas, P. Rappold, E. Redhu, S. Puski, A. Wu, F.S. Jänne, P.A.